REVIEW article
Front. Med.
Sec. Gastroenterology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1544601
This article is part of the Research TopicStem Cell Research and Therapy for Liver and Kidney DiseasesView all 5 articles
Current Status of Pharmacotherapy for Primary
Provisionally accepted
- 1Department of Anesthesiology, First Hospital, Jilin University, Changchun, China
- 2Cadre Ward Ultrasound Department, Diagnostic Ultrasound Center, First Hospital of Jilin University, Changchun, Hebei Province, China
- 3First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China
- 4Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China
- 5Department of Intensive Care Medicine, First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Primary sclerosing cholangitis (PSC) represents a cholestatic disease hallmarked by persistent and progressive inflammation of the bile ducts. Despite its low incidence and unfavorable prognosis, there is no pharmacological therapy capable of altering the course of PSC, and liver transplantation is the only effective treatment. In the face of the landscape of PSC, pharmaceutical therapy encounters great challenges that demand expeditious resolution. However, at present, many drugs have been carried out to phase III clinical trials and are expected to be applied to the clinical treatment of PSC patients in the future. This review integrates relevant research findings from PubMed and Web of Science databases up to October 2024 over the past decade, excluding other liver diseases, such as fatty liver disease, viral hepatitis, and alcoholic liver disease. It covers the vast majority of drugs currently in clinical trials, and focus on the summary of hot research drugs，and summarizes the latest drug-based therapeutic for PSC. This review not only provides certain information for clinical research and treatment of PSC, but it is also the first time that stem cell therapy has been linked to PSC, which is expected to improve cholestasis and liver inflammation in patients with PSC. The article provides explanations and comparisons of different drugs, offering a basis for future researchers to choose medications.PSC is characterized by inflammatory destruction of intrahepatic or extrahepatic bile ducts, leading to bile stasis, fibrosis, and ultimately cirrhosis. According to the latest
Keywords: primary sclerosing cholangitis, Ursodeoxycholic Acid, Nor-UDCA, Clinical trail, Drug Therapy
Received: 13 Dec 2024; Accepted: 10 Jun 2025.
Copyright: © 2025 Yang, Zhen, Huang, Chen, Cui, Sheng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hang Yang, Department of Anesthesiology, First Hospital, Jilin University, Changchun, China
Xia Sheng, Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, 130033, Jilin Province, China
Xinyu Li, Department of Intensive Care Medicine, First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.